Pharma IQ | 07/15/2010
Dr. Andy Bell, Research Fellow at Sandwich Laboratories Worldwide R&D, Pfizer, shares his insights on Pfizer's review of their screening file, prior to the merger with Wyeth in 2009. He also discusses with Pharma IQ, how they identified areas where improvements could be made to the quality of the collection.
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
SmartLab Exchange USA
April 20-21, 2026
The Logan, Philadelphia, USA
Register Now |
View Agenda |
Learn More